ATS Breathe Easy

Career paths are rarely straight roads, instead taking unexpected twists and turns. Past ATS President M. Patricia Rivera, MD, ATSF, tells host Ugo Ezema, Tulane, how her career shifted and changed as she grew as both a professional and a person. She also provides advice for those early and mid-career professionals who are thinking about their next moves and how to navigate challenges that may come up along the way.

What does it take to go from your first ATS international conference to becoming ATS president? Raed Dweik, MD, MBA, ATSF, immediate past-president of the ATS, discusses his journey from an attendee in 1994 to becoming a part of the ATS community, ultimately serving as ATS President in 2024-2025. He discusses his legacy, how important the international conference is to building community, and more with host Ugo Ezema, MD, Tulane.

Currently, there are three treatments currently available for the treatment of pulmonary hypertension, which all work to slow the rate of loss of lung function. However, the treatment landscape is likely to evolve with the positive TETON trials demonstrating that inhaled treprostinil has independent antifibrotic properties. Expert Steven Nathan, MD, Inova, looks ahead to the future of disease-modifying therapies and what these advances mean for patients and pulmonologists, with host Ugo Ezema, MD, Tulane.

Did you know there might be a state chapter of the ATS near you? Host Erika Moseson, MD, MA, Oregon Thoracic Society, talks with Edward Kilb, MD, ATSF, South Carolina Thoracic Society, and W. Dwight Miller, MD, MS, Florida Thoracic Society, about the vital role of ATS state chapters in education, professional development, community building, and advocacy. They discuss how local chapters connect respiratory professionals with their communities, and how clinicians can turn patient experiences and scientific knowledge into meaningful advocacy.
Learn more about ATS Chapters: https://site.thoracic.org/membership/chapters

While most people are familiar with HER2 in regards to breast cancer,  there are HER2 mutations in lung cancer. On this episode of the ATS Breathe Easy podcast, host Patti Tripathi explores HER2-mutant non-small cell lung cancer (NSCLC), an uncommon but increasingly treatable form of lung cancer. Oncologist Christine Lovly, MD, PhD, City of Hope, explains the rapidly evolving science behind HER2 testing and targeted therapies, while patient Nicole Field shares her experience living with stage IV HER2-mutant lung cancer.
For more resources, check out these organizations:
LUNGevity Foundation: https://www.lungevity.org/
International Cancer Advocacy Network: https://askican.org/
Rexanna’s Foundation: https://rexannasfoundation.org/